Abstract
Despite evidence for the efficacy of thrombolytic therapy in acute ischemic stroke, only 1 to 7% of patients receive this therapy. The authors sought to determine the reasons for exclusion from tissue plasminogen activator (tPA) in an acute setting and found avoidable causes in 18% of patients. Improvements in intrahospital coordination would increase the number of patients who might benefit from tPA treatment at the authors' center.
MeSH terms
-
Acute Disease
-
Aged
-
Aged, 80 and over
-
Brain Ischemia / diagnosis
-
Brain Ischemia / drug therapy*
-
Brain Ischemia / epidemiology
-
Cerebral Hemorrhage / drug therapy
-
Cerebral Hemorrhage / epidemiology
-
Cerebral Infarction / drug therapy
-
Cerebral Infarction / epidemiology
-
Contraindications
-
Early Diagnosis
-
Emergency Service, Hospital / statistics & numerical data*
-
Female
-
Fibrinolytic Agents / therapeutic use*
-
Humans
-
Ischemic Attack, Transient / drug therapy
-
Ischemic Attack, Transient / epidemiology
-
Male
-
Middle Aged
-
Neurology
-
Recombinant Proteins / therapeutic use
-
Referral and Consultation / statistics & numerical data
-
Third-Party Consent
-
Thrombolytic Therapy / statistics & numerical data*
-
Time Factors
-
Tissue Plasminogen Activator / therapeutic use*
-
Treatment Refusal
Substances
-
Fibrinolytic Agents
-
Recombinant Proteins
-
Tissue Plasminogen Activator